Nolen W A, Haffmans P M, Bouvy P F, Duivenvoorden H J
Psychiatric Centre Bloemendaal, Department of Biological Psychiatry, The Hague, The Netherlands.
J Affect Disord. 1993 Jul;28(3):189-97. doi: 10.1016/0165-0327(93)90104-r.
In a double-blind study the selective monoamine oxidase-A inhibitor brofaromine was compared with the classical MAOI tranylcypromine in 39 patients with major depression resistant to treatment with tricyclic antidepressants. Concerning efficacy no significant differences were found. Ten out of 22 patients responded to brofaromine and 5 out of 17 patients to tranylcypromine. Adverse effects favoured brofaromine. Although orthostatic hypotension occurred in both groups, severe decrease in blood pressure and dizziness occurred significantly more with tranylcypromine. Both MAOIs caused a decrease in stage 4 and REM sleep and an increase in REM latency. In most patients receiving tranylcypromine REM sleep was completely abolished.
在一项双盲研究中，对39例对三环类抗抑郁药治疗无效的重度抑郁症患者，将选择性单胺氧化酶-A抑制剂溴法罗明与经典单胺氧化酶抑制剂反苯环丙胺进行了比较。在疗效方面未发现显著差异。22例患者中有10例对溴法罗明有反应，17例患者中有5例对反苯环丙胺有反应。不良反应方面溴法罗明更具优势。虽然两组均出现体位性低血压，但反苯环丙胺导致的严重血压下降和头晕明显更多。两种单胺氧化酶抑制剂均导致4期睡眠和快速眼动睡眠减少，快速眼动睡眠潜伏期延长。在大多数接受反苯环丙胺治疗的患者中，快速眼动睡眠完全消失。
